Sali Pharmaceutical: Four varieties of the company and its subsidiaries have been selected for the 2026 National Essential Medicines List.

Sali Pharmaceutical announced that the "National Essential Drug List" jointly issued by the National Health Commission and two other departments will take effect on September 1st. The company and its subsidiary, Qinghai Zhufeng Dongchongxiacao Pharmaceutical Co., Ltd., have 4 varieties selected, among which Bailing Capsules are newly included, while Wuling Capsules, Lingze Tablets, and Bailin Tablets continue to be included. This is conducive to promoting the coverage of related products in various medical institutions, promoting market expansion, but product sales are affected by multiple factors, reminding investors to pay attention to risks.